DEA-DCI-DIR-001-23 Unclassified
These effects are based on changes in lactate levels and participation in metabolic activities
Current UK regulatory position includes: Warnings and precautions regarding thyroid C-cell tumours based on animal data, with acknowledgement that human relevance is uncertain Advice regarding pancreatitis risk, with recommendations to discontinue if acute pancreatitis is suspected and not to restart if confirmed No restrictions based on general cancer risk, as human evidence does not support an increased overall malignancy risk Monitoring for gallbladder disease, which has been associated with GLP-1 receptor agonist use The Summary of Product Characteristics (SmPC) for each GLP-1 medicine includes detailed safety information that healthcare professionals should review before prescribing
When a patients blood pressure is lower, their blood sugars improve, they can take a medication out of their daily regimen [sit] comfortably on an airplane without a seat belt extender, or [be] able to play with a young child without huffing and puffing, those are the changes that really improve quality of life. 3
Simizu, S., Suzuki, T., Muroi, M., Lai, N
